Please assess the completion status of the following clinical trial:

Trial Title: M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age of 18 years or older~* Confirmed pancreatic ductal adenocarcinoma~* Metastatic disease as documented by CT scan or MRI (locally advanced disease only NOT eligible)~* At least 1 site of disease measurable by RECIST ver1.1~* ECOG performance status of 0 to 1~* Adequate bone marrow, renal capacity and hepatic function~* Willing to administer daily subcutaneous injections at home~Exclusion Criteria:~* Any prior radiotherapy, chemotherapy, surgery, or investigational therapy for adjuvant or metastatic pancreatic cancer~* History of suspected history, or presence of heparin induced toxicity (w/ or w/o thrombosis)~* History of unexplained bleeding episodes within 3 months of M402 dosing~* Received thrombolytic agents w/in the previous month~* Had full-dose anticoagulation with heparin, enoxaparin, dalteparin, other LMWH, a/or other anticoagulants w/in 90 days before first dose of M402~* High cardiovascular risk, including but not limited to, recent coronary stenting or myocardial infarction in the past year~* Major trauma or surgery w/in prior 4 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- nab-paclitaxel, gemcitabine, placebo (Type: PLACEBO_COMPARATOR): Part A: Not applicable.~Part B: nab-paclitaxel, gemcitabine, and placebo. Placebo administered daily along with nab-paclitaxel and gemcitabine administration on Day 1, Day 8, and Day 15 of each 28-day cycle.
- nab-paclitaxel, gemcitabine, necuparanib (Type: EXPERIMENTAL): Part A: Following a single-dose of necuparanib and a 7-day follow-up period, necuparanib was administered daily along with nab-paclitaxel and gemcitabine administration on Day 1, Day 8, and Day 15 of each 28-day cycle. Dose escalation of necuparanib proceeded by cohort in a 3+3 design.~Part B: A fixed dose of necuparanib will be administered daily along with nab-paclitaxel and gemcitabine administration on Day 1, Day 8, and Day 15 of each 28-day cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).